Treg vaccination in autoimmune type 1 diabetes
Serr I, Weigmann B, Franke RK, Daniel C (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Adis
Book Volume: 28
Pages Range: 7-16
Journal Issue: 1
DOI: 10.1007/s40259-013-0060-3
Abstract
Foxp3? regulatory T (Treg) cells are critical contributors to the establishment and maintenance of immunological self-tolerance. Autoimmune type 1 diabetes (T1D) is characterized by the loss of self-tolerance to the insulin-producing ? cells in the pancreas and the destruction of ? cells, resulting in the development of chronic hyperglycemia at diagnosis. The application of strong agonistic T-cell receptor ligands provided under subimmunogenic conditions functions as a critical means for the efficient de novo conversion of naive CD4? T cells into Foxp3? Treg cells. The specific induction of Treg cells upon supply of strong-agonistic variants of certain self-antigens could therefore function as a critical instrument in order to achieve safe and specific prevention of autoimmunity such as T1D via the restoration of self-tolerance. Such immunotherapeutic strategies are being developed, and in the case of T1D aim to restrict autoimmunity and ?-cell destruction. In this review, we discuss the requirements and opportunities for Treg-based tolerance approaches with the goal of interfering with autoimmune T1D.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Serr, I., Weigmann, B., Franke, R.K., & Daniel, C. (2014). Treg vaccination in autoimmune type 1 diabetes. Biodrugs, 28(1), 7-16. https://doi.org/10.1007/s40259-013-0060-3
MLA:
Serr, Isabelle, et al. "Treg vaccination in autoimmune type 1 diabetes." Biodrugs 28.1 (2014): 7-16.
BibTeX: Download